Skip to main content
. 2023 Aug 17;12(8):1328. doi: 10.3390/antibiotics12081328

Table 3.

Characteristics of case reports included in the review of the literature and our cases.

Ceftazidime/Avibactam Outcome
First Author and Year Bacterium Mechanism of Resistance Dosage Antibiotics Combination Treatment (days) Surgical Treatment Clinical Cure Microbiological Cure
Cani E, 2017 [8] K. pneumoniae N/A 2.5 g t.i.d. Amikacin 42 Yes Yes N/A
Rico-Nieto A, 2018 [9] K. pneumoniae OXA-48 2.5 g t.i.d. Colistin 56 Yes Yes N/A
De León-Borrás R, 2018 [10] K. pneumoniae KPC N/A Amikacin,
polymyxin B
42 No Yes N/A
Rodríguez-Núñez O, 2018 [11] P. aeruginosa N/A N/A Tobramycin,
ciprofloxacin
34 Yes No Yes
Mittal J, 2018 [12] K. pneumoniae NDM,
OXA-181
2.5 g t.i.d. Aztreonam 46 Yes Yes Yes
Schimmenti A, 2018 [13] K. pneumoniae KPC 2.5 g t.i.d. None 14 Yes Yes Yes
Alamarat ZI, 2020 [14] P. aeruginosa
K. pneumoniae
NDM-1
KPC
2.5 g t.i.d. Aztreonam 14 Yes No N/A
Meschiari A, 2021 [15] P. aeruginosa
K. pneumoniae
P. aeruginosa
N/A
KPC
N/A
2.5 g q.i.d.
2.5 g t.i.d.
Aztreonam
Aztreonam
42
56
Yes
Yes
Yes
Yes
N/A
N/A
Mularoni A, 2021 [16] P. aeruginosa VIM-1 2.5 g t.i.d. Amikacin,
aztreonam
42 Yes Yes Yes
Ji Z, 2021 [17] K. pneumoniae N/A 2.5 g t.i.d. None 21 Yes Yes Yes
Eskenazi A, 2022 [18] K. pneumoniae OXA-48 2.5 g t.i.d. Moxifloxacin,
phage
88 Yes Yes Yes
Racenis K, 2022 [19] P. aeruginosa KPC 2.5 g t.i.d. Phage 15 Yes No No
Rubnitz ZA, 2022 [20] C. sedlakii NDM 2.5 g t.i.d. Aztreonam 42 Yes No Yes
Present cases, 2023 P. aeruginosa
P. aeruginosa
P. aeruginosa
N/A
N/A
N/A
2.5 g t.i.d.
2.5 g t.i.d.
2.5 g t.i.d.
None
Fosfomycin
Amikacin
42
42
42
No
Yes
Yes
Yes
Yes
Yes
N/A
N/A
N/A

N/A, not available.